141 related articles for article (PubMed ID: 38387093)
1. Treatment of congenital Langerhans cell histiocytosis with cobimetinib.
Benjelloun G; Roquet-Gravy C; Marot L; Secco LP; Roquet-Gravy PP; Baeck M; Bulinckx A
Pediatr Dermatol; 2024; 41(3):515-517. PubMed ID: 38387093
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S
J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
5. Progressive nodular histiocytosis in a 9-year-old boy treated with cobimetinib.
Buján MM; Sánchez La Rosa C; Galluzzo Mutti ML; Braier J; Diamond EL
Pediatr Dermatol; 2022 Jan; 39(1):115-118. PubMed ID: 34935192
[TBL] [Abstract][Full Text] [Related]
6. Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy.
Lin HT; Wikenheiser-Brokamp KA; Udstuen G; Jones B; McCormack FX
Chest; 2023 Feb; 163(2):e53-e56. PubMed ID: 36759117
[TBL] [Abstract][Full Text] [Related]
7. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
[TBL] [Abstract][Full Text] [Related]
8. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
9. A circulating subset of BRAF
Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
Li Q
J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
[TBL] [Abstract][Full Text] [Related]
11. Multiple arterial thrombosis and pericarditis revealing histiocytosis successfully treated with MEK-inhibitor cobimetinib.
Razanamahery J; Malakhia A; Guillon B; Humbert S; Magy-Bertrand N
Clin Exp Rheumatol; 2020; 38(1):173-174. PubMed ID: 31376269
[No Abstract] [Full Text] [Related]
12. Treatment of Cerebral Histiocytosis With Low Dose of Cobimetinib: A Report of 2 Cases.
Schubert C; Schiffmann I; Farschtschi SC; Emile JF; Friese MA
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200233. PubMed ID: 38588479
[TBL] [Abstract][Full Text] [Related]
13. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
14. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
15. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
[TBL] [Abstract][Full Text] [Related]
16. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
[TBL] [Abstract][Full Text] [Related]
17.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
[TBL] [Abstract][Full Text] [Related]
19. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.
Kansal R; Quintanilla-Martinez L; Datta V; Lopategui J; Garshfield G; Nathwani BN
Genes Chromosomes Cancer; 2013 Jan; 52(1):99-106. PubMed ID: 22996177
[TBL] [Abstract][Full Text] [Related]
20. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
